[go: up one dir, main page]

PE20140966A1 - Quinazolincarboxamida azetidinas - Google Patents

Quinazolincarboxamida azetidinas

Info

Publication number
PE20140966A1
PE20140966A1 PE2013001281A PE2013001281A PE20140966A1 PE 20140966 A1 PE20140966 A1 PE 20140966A1 PE 2013001281 A PE2013001281 A PE 2013001281A PE 2013001281 A PE2013001281 A PE 2013001281A PE 20140966 A1 PE20140966 A1 PE 20140966A1
Authority
PE
Peru
Prior art keywords
quinazoline
azethydines
hal
ethylamine
carboxyl
Prior art date
Application number
PE2013001281A
Other languages
English (en)
Inventor
Bayard R Huck
Reinaldo Jones
Yufang Xiao
Constantin Neagu
Donald Bankston
Andreas Goutopoulos
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20140966A1 publication Critical patent/PE20140966A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE AUN COMPUESTO DE FORMULA (I) Y SUS ESTEREOISOMEROS, TAUTOMEROS, ENTRE OTROS, EN DONDE: R1 ES H; R2 ES HAL, AR, CONH2, ENTRE OTROS; R3', R3", SON H, LA O HAL; AR ES UN HETEROCICLO AROMATICO MONO, BICICLICO QUE TIENE 0, 1, 2, 3, 4 ATOMOS DE N, O ENTRE OTROS. SON COMPUESTOS PREFERIDOS AMIDA DEL ACIDO 4-[(S)-2-AZETIDIN-1-IL-1-(3-FLUOROFENIL)-ETILAMINO]-QUINAZOLIN-8-CARBOXILICO; AMIDA DEL ACIDO 4-[(S)-2-AZETIDIN-1-IL-1-(3-CLOROFENIL)-ETILAMINO]-QUINAZOLIN-8-CARBOXILICO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, SIENDO UTIL PARA EL TRATAMINETO DE ENFERMEDADES HIPERPROLIFERATIVAS
PE2013001281A 2010-11-24 2011-11-11 Quinazolincarboxamida azetidinas PE20140966A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41713110P 2010-11-24 2010-11-24

Publications (1)

Publication Number Publication Date
PE20140966A1 true PE20140966A1 (es) 2014-08-06

Family

ID=45001695

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001281A PE20140966A1 (es) 2010-11-24 2011-11-11 Quinazolincarboxamida azetidinas

Country Status (30)

Country Link
US (1) US8946247B2 (es)
EP (1) EP2643313B9 (es)
JP (1) JP5897590B2 (es)
KR (1) KR101894116B1 (es)
CN (1) CN103228649B (es)
AR (1) AR093725A1 (es)
AU (1) AU2011334173B2 (es)
BR (1) BR112013012488B1 (es)
CA (1) CA2818706C (es)
CL (1) CL2013001459A1 (es)
CO (1) CO6721019A2 (es)
DK (1) DK2643313T3 (es)
EA (1) EA023821B1 (es)
ES (1) ES2594404T3 (es)
HR (1) HRP20161183T1 (es)
HU (1) HUE028967T2 (es)
IL (1) IL226233A (es)
LT (1) LT2643313T (es)
MX (1) MX355325B (es)
MY (1) MY186456A (es)
NZ (1) NZ612224A (es)
PE (1) PE20140966A1 (es)
PL (1) PL2643313T3 (es)
PT (1) PT2643313T (es)
RS (1) RS55204B1 (es)
SG (1) SG190318A1 (es)
SI (1) SI2643313T1 (es)
UA (1) UA112167C2 (es)
WO (1) WO2012069146A1 (es)
ZA (1) ZA201304637B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347241B (es) 2011-09-12 2017-04-20 Merck Patent Gmbh Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
RS56534B1 (sr) 2011-09-12 2018-02-28 Merck Patent Gmbh Novi imidazol akmini kao modulatori aktivnosti kinaza
CN110078743A (zh) 2012-11-16 2019-08-02 默克专利有限公司 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
MX2015006516A (es) * 2012-11-29 2015-08-14 Merck Patent Gmbh Derivados de azaquinolin-carboxamida.
AU2014228385B2 (en) 2013-03-11 2018-08-09 Merck Patent Gmbh 6-[4-(1-H-imidazol-2-yl]piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
US9980966B2 (en) 2014-04-03 2018-05-29 Merck Patent Gmbh Combinations of cancer therapeutics
BR112017010232A2 (pt) * 2014-12-11 2018-01-02 Merck Patent Gmbh Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um derivado de quinazolina
US20190054110A1 (en) * 2016-02-16 2019-02-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
WO2017140803A1 (en) * 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
CA3201799A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
CN116490187A (zh) * 2020-11-16 2023-07-25 默克专利股份公司 用于癌症治疗的激酶抑制剂组合
US11866421B2 (en) * 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2004014873A1 (ja) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7189729B2 (en) 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
AU2004283751B2 (en) 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
MXPA06006651A (es) 2003-12-09 2006-08-11 Gov Health & Human Serv Metodos para suprimir una respuesta inmune o un tratamiento para un trastorno proliferativo.
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
CN102317269B (zh) 2009-02-11 2015-06-17 默克专利有限公司 新氨基氮杂杂环甲酰胺类
US9586938B2 (en) * 2010-07-29 2017-03-07 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди

Also Published As

Publication number Publication date
MY186456A (en) 2021-07-22
AU2011334173B2 (en) 2015-07-16
EP2643313A1 (en) 2013-10-02
RS55204B1 (sr) 2017-01-31
KR101894116B1 (ko) 2018-08-31
EP2643313B9 (en) 2017-02-22
EP2643313B1 (en) 2016-06-29
HK1188444A1 (zh) 2014-05-02
CA2818706C (en) 2019-07-23
US20130252942A1 (en) 2013-09-26
IL226233A (en) 2017-07-31
BR112013012488B1 (pt) 2021-08-31
MX355325B (es) 2018-04-16
CN103228649A (zh) 2013-07-31
US8946247B2 (en) 2015-02-03
JP5897590B2 (ja) 2016-03-30
EA023821B1 (ru) 2016-07-29
NZ612224A (en) 2015-01-30
CL2013001459A1 (es) 2013-12-27
AR093725A1 (es) 2015-06-24
LT2643313T (lt) 2016-10-25
PL2643313T3 (pl) 2017-03-31
CA2818706A1 (en) 2012-05-31
SG190318A1 (en) 2013-06-28
UA112167C2 (uk) 2016-08-10
PT2643313T (pt) 2016-10-11
CO6721019A2 (es) 2013-07-31
ZA201304637B (en) 2014-03-26
MX2013005751A (es) 2013-08-01
SI2643313T1 (sl) 2016-11-30
IL226233A0 (en) 2013-07-31
EA201300610A1 (ru) 2013-12-30
DK2643313T3 (en) 2016-10-24
ES2594404T3 (es) 2016-12-20
AU2011334173A1 (en) 2013-05-02
CN103228649B (zh) 2015-11-25
HRP20161183T1 (hr) 2016-11-04
WO2012069146A1 (en) 2012-05-31
HUE028967T2 (en) 2017-01-30
BR112013012488A2 (pt) 2016-07-19
JP2013544257A (ja) 2013-12-12
KR20130130753A (ko) 2013-12-02

Similar Documents

Publication Publication Date Title
PE20140966A1 (es) Quinazolincarboxamida azetidinas
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
PE20091843A1 (es) Inhibidores de catepsina c
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
MX358311B (es) Compuesto heterociclico que contiene nitrogeno o sal del mismo.
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
IN2012DN02502A (es)
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
UA103329C2 (ru) Соли соединений-ингибиторов вич
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
MX369508B (es) Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos.
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
CO6710902A2 (es) Inhibidores de oxadiazol de la producción de leucotrienos
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
UY31824A (es) Nuevos compuestos
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
FG Grant, registration